Moderna

Moderna, Inc. is a globally recognized biotechnology company specializing in messenger RNA (mRNA) medicines and vaccines. Established in 2010 and headquartered in Cambridge, Massachusetts, USA, the company has transformed the biotechnology industry through its pioneering mRNA platform. Moderna gained worldwide prominence with the rapid development of one of the first authorized COVID-19 vaccines, demonstrating the potential of mRNA technology for preventing and treating infectious diseases.

Today, Moderna’s research extends far beyond vaccines, with an expanding pipeline focused on oncology, rare diseases, respiratory illnesses, cardiovascular disorders, autoimmune diseases, and personalized cancer therapies. The company combines computational biology, artificial intelligence, genomics, and advanced manufacturing technologies to accelerate drug discovery and clinical development.

Moderna operates state-of-the-art research laboratories, manufacturing facilities, and commercial operations across North America, Europe, and other international markets. The company collaborates with governments, academic institutions, healthcare organizations, and biotechnology partners worldwide to advance scientific innovation and improve global public health. Its commitment to continuous research, high manufacturing standards, and sustainable operations has positioned Moderna among the world’s leading biotechnology innovators. By leveraging its proprietary mRNA platform, Moderna continues to develop next-generation medicines that have the potential to address a broad range of serious diseases and reshape the future of modern healthcare.